Sera Prognostics, Inc. SERA
We take great care to ensure that the data presented and summarized in this overview for SERA PROGNOSTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SERA
View all-
Baker Bros. Advisors LP New York, NY5.5MShares$18.2 Million0.15% of portfolio
-
Whetstone Capital Advisors, LLC Shawnee Mission, KS3.63MShares$12 Million3.67% of portfolio
-
Interwest Venture Management CO2.42MShares$8 Million21.78% of portfolio
-
Abrdn PLC2.23MShares$7.37 Million0.01% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.65MShares$5.46 Million0.97% of portfolio
-
Black Rock Inc. New York, NY1.41MShares$4.67 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$3.85 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY719KShares$2.38 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY681KShares$2.25 Million0.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il629KShares$2.08 Million0.0% of portfolio
Latest Institutional Activity in SERA
Top Purchases
Top Sells
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Insider Transactions at SERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2025
|
Tiffany Eul Davis Inglis Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Oct 07
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.0%
|
$6,000
$3.18 P/Share
|
|
Oct 06
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
227
-0.39%
|
$681
$3.16 P/Share
|
|
Sep 11
2025
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,395
-0.87%
|
$4,185
$3.13 P/Share
|
|
Sep 11
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
645
-0.64%
|
$1,935
$3.13 P/Share
|
|
Sep 11
2025
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
934
-0.73%
|
$2,802
$3.13 P/Share
|
|
Sep 11
2025
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
1,271
-0.72%
|
$3,813
$3.13 P/Share
|
|
Sep 11
2025
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,246
-0.4%
|
$9,738
$3.13 P/Share
|
|
Sep 11
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
915
-0.32%
|
$2,745
$3.13 P/Share
|
|
Sep 09
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,263
-1.81%
|
$15,789
$3.15 P/Share
|
|
Sep 09
2025
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,158
-2.54%
|
$63,474
$3.15 P/Share
|
|
Sep 09
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.95%
|
$6,000
$3.05 P/Share
|
|
Sep 09
2025
|
Sandra Aj Lawrence |
SELL
Open market or private sale
|
Direct |
3,899
-17.17%
|
$11,697
$3.05 P/Share
|
|
Sep 05
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
222
-0.38%
|
$666
$3.35 P/Share
|
|
Sep 02
2025
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
1,458
-0.82%
|
$4,374
$3.49 P/Share
|
|
Aug 29
2025
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
10,542
-5.58%
|
$31,626
$3.49 P/Share
|
|
Aug 20
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
6,000
-5.53%
|
$12,000
$2.22 P/Share
|
|
Aug 08
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,800
-1.96%
|
$11,600
$2.54 P/Share
|
|
Aug 08
2025
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,094
-4.22%
|
$14,188
$2.54 P/Share
|
|
Aug 08
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
5,962
-5.21%
|
$11,924
$2.54 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 608K shares |
|---|---|
| Exercise of conversion of derivative security | 37.5K shares |
| Open market or private sale | 444K shares |
|---|